Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Wednesday, November 30, 2022. Graham has battled excess weight for years, cycling through trendy diets, various drugs, and even bariatric surgery. she started a new medication, Mounjaro ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been ... weight-loss medications more than doubled between 2022 and 2023. Meanwhile, they have also been found to ...

it has been barred by an old federal law from paying for weight-loss drugs. But last November Biden proposed new rules to allow Medicare and Medicaid to pay for these meds. The change would not ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Weight loss ... drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.